Sun Pharmaceutical Industries Ltd
SUNPHARMASun Pharmaceutical Industries Ltd
SUNPHARMA![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/largecap.png)
![](https://assets.tickertape.in/sector-icons/low_risk.png)
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
41.74 | 5.96 | 0.81% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 34 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
Investor Presentation
View olderPeers
Compare with peersZydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 29,145.28 | 32,201.59 | 27,328.22 | 30,091.40 | 33,489.09 | 34,357.31 | 39,729.96 | 44,520.20 | 49,887.17 | 49,851.04 | ||||||||||
Raw Materials | 6,724.15 | 8,402.37 | 7,193.98 | 8,302.08 | 8,929.60 | 9,328.30 | 10,459.15 | 11,349.07 | 10,370.48 | 35,968.04 | ||||||||||
Power & Fuel Cost | 545.44 | 525.09 | 559.97 | 613.60 | 621.89 | 627.09 | 702.78 | 830.05 | 760.78 | |||||||||||
Employee Cost | 4,772.31 | 4,902.30 | 5,367.05 | 5,967.09 | 6,362.35 | 6,862.23 | 7,300.83 | 8,296.03 | 9,429.06 | |||||||||||
Selling & Administrative Expenses | 5,219.20 | 5,224.61 | 4,727.00 | 5,350.33 | 6,995.37 | 6,283.41 | 7,366.88 | 9,482.36 | 11,033.19 | |||||||||||
Operating & Other expenses | 3,752.78 | 2,434.80 | 3,983.83 | 3,739.60 | 3,214.78 | 6,235.53 | 7,147.91 | 2,452.83 | 4,410.66 | |||||||||||
EBITDA | 8,131.40 | 10,712.42 | 5,496.39 | 6,118.70 | 7,365.10 | 5,020.75 | 6,752.41 | 12,109.86 | 13,883.00 | 13,883.00 | ||||||||||
Depreciation/Amortization | 1,037.53 | 1,264.75 | 1,499.84 | 1,753.25 | 2,052.78 | 2,079.95 | 2,143.74 | 2,529.43 | 2,556.64 | 2,556.64 | ||||||||||
PBIT | 7,093.87 | 9,447.67 | 3,996.55 | 4,365.45 | 5,312.32 | 2,940.80 | 4,608.67 | 9,580.43 | 11,326.36 | 11,326.36 | ||||||||||
Interest & Other Items | 523.24 | 399.80 | 517.57 | 555.25 | 302.73 | 141.43 | 127.35 | 172.00 | 238.47 | 238.47 | ||||||||||
PBT | 6,570.63 | 9,047.87 | 3,478.98 | 3,810.20 | 5,009.59 | 2,799.37 | 4,481.32 | 9,408.43 | 11,087.89 | 11,087.89 | ||||||||||
Taxes & Other Items | 2,024.92 | 2,083.50 | 1,383.28 | 1,144.78 | 1,244.66 | -104.45 | 1,208.59 | 934.85 | 1,511.51 | 1,511.51 | ||||||||||
Net Income | 4,545.71 | 6,964.37 | 2,095.70 | 2,665.42 | 3,764.93 | 2,903.82 | 3,272.73 | 8,473.58 | 9,576.38 | 9,576.38 | ||||||||||
EPS | 20.30 | 28.98 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 39.91 | ||||||||||
DPS | 1.00 | 3.50 | 2.00 | 2.75 | 4.00 | 7.50 | 10.00 | 11.50 | 13.50 | 12.50 | ||||||||||
Payout ratio | 0.05 | 0.12 | 0.23 | 0.25 | 0.25 | 0.62 | 0.73 | 0.33 | 0.34 | 0.31 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Dr Reddy's Laboratories Ltd | 20.46 | 4.04 | 0.58% |
Price Comparison
Compare SUNPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Value Discovery Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6253% | Percentage of the fund’s portfolio invested in the stock 5.50% | Change in the portfolio weight of the stock over the last 3 months -0.60% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 9/95 (-2) |
ICICI Prudential Bluechip Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3577% | Percentage of the fund’s portfolio invested in the stock 2.58% | Change in the portfolio weight of the stock over the last 3 months -0.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/80 (0) |
ICICI Prudential India Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3548% | Percentage of the fund’s portfolio invested in the stock 6.74% | Change in the portfolio weight of the stock over the last 3 months 3.05% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/84 (+4) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd
Events
Dividend Trend
Increasing Dividends
SUNPHARMA has increased dividends consistently over the last 5 years
Dividend Yield
Current dividend yield is 0.81%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.10 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateFeb 9, 2024
Dividend/Share
₹8.50
Ex DateEx Date
Feb 9, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateFeb 8, 2023
Dividend/Share
₹7.50
Ex DateEx Date
Feb 8, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Dividend/Share
₹3.00
Ex DateEx Date
Aug 19, 2022
Bulls back on D-Street: Investors gain Rs 7 lakh crore as Sensex, Nifty rebound
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202407/66a38884dc168-market-cap-of-bse-listed-firms-climbed-rs-71-lakh-crore-to-rs-45692-lakh-crore-on-friday-the-mark-262907804-16x9.jpg)
Sun Pharma receives USFDA approval for LEQSELVI (deuruxolitinib) 8 mg tablets
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Sun Pharmaceuticals Industries announced that the U.S. Food and Drug Administration (FDA) approved LEQSELVI' (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. 'LEQSELVI offers a new and effective solution that will significantly enhance options for long-suffering patients battling severe alopecia areata and their physicians,' said Abhay Gandhi, CEO, North America Business, Sun Pharma. 'Our fast-growing dermatology business is excited to add this novel treatment to its portfolio.Powered by Capital Market - Live
Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1697.15, up 1.88% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.28% on the day, quoting at 24718.65. The Sensex is at 80971.98, up 1.16%. Sun Pharmaceuticals Industries Ltd has gained around 11.93% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has gained around 10% in last one month and is currently quoting at 21105.5, up 1.71% on the day. The volume in the stock stood at 25.62 lakh shares today, compared to the daily average of 19.27 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1705.5, up 1.91% on the day. Sun Pharmaceuticals Industries Ltd is up 49.54% in last one year as compared to a 25.73% jump in NIFTY and a 43.88% jump in the Nifty Pharma index.The PE of the stock is 130.91 based on TTM earnings ending March 24.Powered by Capital Market - Live
Sun Pharma hits all time high on US FDA nod for alopecia drug ‘Leqselvi’
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2018-12/01/thumb/featurecrop/400X400/1543610764-3396.jpg)
Sun Pharma receives US FDA approval for drug to treat alopecia areata
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/article/2023-03/26/thumb/featurecrop/400X400/1679847073-2245.jpg)
Sun Pharma gets US FDA nod for its specialty drug against baldness
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-112034529,width-1200,height-630,imgsize-30662,overlay-economictimes/photo.jpg)
The domestic equity indices traded with robust gains in the mid-morning trade. The Nifty scaled above the 24,600 level. IT shares gained after declining in the past trading session. At 11:30 IST, the barometer index, the S&P BSE Sensex, was up 646.71 points or 0.80% to 80,678.94. The Nifty 50 index rallied 235.35 points or 0.95% to 24,638.95. The broader market outperformed the headline indices. The S&P BSE Mid-Cap index gained 1.70% and the S&P BSE Small-Cap index added 1.11%. The market breadth was strong. On the BSE, 2,701 shares rose and 1,040 shares fell. A total of 115 shares were unchanged. Buzzing Index: The Nifty IT index added 1.96% to 40,839.70. The index shed 0.03% in the past trading sessions. Mphasis (up 6.77%), LTIMindtree (up 2.61%), Infosys (up 2.53%), Wipro (up 2.25%), HCL Technologies (up 2.11%), Persistent Systems (up 2.01%), Tata Consultancy Services (up 1.37%), Coforge (up 0.78%), L&T Technology Services (up 0.1%) advanced. Stocks in Spotlight: Sun Pharmaceutical Industries gained 2.58% after the pharma major said that it has received approval from the U.S. Food and Drug Administration (US FDA) for LEQSELVI (deuruxolitinib), an oral JAK Inhibitor for the treatment of severe alopecia areata. VST Industries added 2.79% after the company said that its board has recommended issue of bonus shares in the ratio of 10:1, i.e. ten new bonus equity shares of Rs 10 each for every one existing fully paid equity share of Rs 10 each. Tech Mahindra shed 0.29%. The IT major's consolidated net profit jumped 28.82% to Rs 851.5 crore on 1.04% rise in revenue from operations to Rs 13,005.5 crore in Q1 FY25 over in Q1 FY24. Global Markets: Asian stocks traded mixed on Friday as investors digested Tokyo's latest inflation data and awaited key U.S. economic figures. Japan's headline inflation eased slightly to 2.2% in July, while core inflation held steady at 2.2%. The market's focus now shifts to the U.S., where the release of the personal consumption expenditure (PCE) index ' the Federal Reserve's preferred inflation gauge ' is expected to influence interest rate expectations. Meanwhile, U.S. stocks experienced a rotation away from technology shares on Thursday, with the Nasdaq Composite and S&P 500 declining. The Dow Jones Industrial Average bucked the trend with a modest gain. This shift is a common occurrence during bull markets as market leadership evolves.Powered by Capital Market - Live
Sun Pharma’s drug to treat alopecia areata gets USFDA nod
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-112033065,width-1200,height-630,imgsize-29922,overlay-economictimes/photo.jpg)
Sun Pharmaceutical Industries Share Price Today Live Updates: Sun Pharma Closes at Rs 1665.80 with 6.19% Weekly Gain - The Economic Times
![](https://pocket-image-cache.com/direct?url=http://economictimes.indiatimes.com/thumb/msid-112029605,width-600,resizemode-4,imglength-72289/markets/stocks/stock-liveblog/sun-pharmaceutical-industries-share-price-today-live-updates-26-jul-2024.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 13.29% to 13.56%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.15%